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group Lp penalized global AUC maximization
Zhenqiu Liu1,2*, Laurence S Magder2, Terry Hyslop3, Li Mao4

Abstract
It has been demonstrated that genes in a cell do not act independently. They interact with one another to complete certain biological processes or to implement certain molecular functions. How to incorporate biological pathways or functional groups into the model and identify survival associated gene pathways is still a challenging
problem. In this paper, we propose a novel iterative gradient based method for survival analysis with group Lp
penalized global AUC summary maximization. Unlike LASSO, Lp (p < 1) (with its special implementation entitled
adaptive LASSO) is asymptotic unbiased and has oracle properties [1]. We first extend Lp for individual gene identification to group Lp penalty for pathway selection, and then develop a novel iterative gradient algorithm for penalized global AUC summary maximization (IGGAUCS). This method incorporates the genetic pathways into global
AUC summary maximization and identifies survival associated pathways instead of individual genes. The tuning
parameters are determined using 10-fold cross validation with training data only. The prediction performance is
evaluated using test data. We apply the proposed method to survival outcome analysis with gene expression profile and identify multiple pathways simultaneously. Experimental results with simulation and gene expression data
demonstrate that the proposed procedures can be used for identifying important biological pathways that are
related to survival phenotype and for building a parsimonious model for predicting the survival times.
Background
Biologically complex diseases such as cancer are caused
by mutations in biological pathways or functional
groups instead of individual genes. Statistically, genes
sharing the same pathway have high correlations and
form functional groups or biological pathways. Many
databases about biological knowledge or pathway information are available in the public domain after many
years of intensive biomedical research. Such databases
are often named metadata, which means data about
data. Examples of such databases include the gene
ontology (GO) databases (Gene Ontology Consortium,
2001), the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database [2], and several other pathways on the
internet (e.g., http://www.superarray.com; http://www.
biocarta.com). Most current methods, however, are
developed purely from computational points without
utilizing any prior biological knowledge or information.
Gene selections with survival outcome data in the
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statistical literature are mainly within the penalized Cox
or additive risk regression framework [3-8]. The L1 and
L p (p < 1) penalized Cox regressions can work for
simultaneous individual gene selection and survival prediction and have been extensively studied in statistics
and bioinformatics literature [8-11]. The performance of
the survival model is evaluated by the global area under
the ROC curve summary (GAUCS) [12]. Unfortunately,
those methods are mainly for individual gene selections
and cannot be used to identify pathways directly. In
microarray analysis, several popular tools for pathway
analysis, including GENMAP, CHIPINFO, and GOMINER, are used to identify pathways that are overexpressed by differentially expressed genes. These gene
set enrichment analysis (GSEA)methods are very informative and are potentially useful for identifying pathways that related to disease status [13]. One drawback
with GSEA is that it considers each pathway separately
and the pathway information is not utilized in the modeling stage. Wei and Li [14] proposed a boosting algorithm incorporating related pathway information for
classification and regression. However, their method can
only be applied for binary phenotypes. Since most
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complex diseases such as cancer are believed to be associated with the activities of multiple pathways, new statistical methods are required to select multiple pathways
simultaneously with the time-to-event phenotypes.
A ROC curve provides complete information on the
set of all possible combinations of true-positive and
false-positive rates, but is also more generally useful as a
graphic characterization of the magnitude of separation
between the case and control distributions. AUC is
known to measure the probability that the marker value
(score) for a randomly selected case exceeds the marker
value for a randomly selected control and is directly
related to the Mann-Whitney U statistic [15,16]. In survival analysis, a survival time can be viewed as a timevarying binary outcome. Given a fixed time t, the
instances for which ti = t are regarded as cases and samples with ti >t are controls. The global AUC summary
(GAUCS) is then defined as GAUCS = P (M j >M k |t j
<tk), which indicates that subject who died at an earlier
time has a larger score value, where M is a score function. Heagerty and Zheng [12] have shown that GAUCS
is a weighted average of the area under time-specific
ROC curves. Liu et al. [17] proposed a L 1 penalized
quadratic support vector machine (SVM) method for
GAUCS maximization and individual gene selection
with survival outcomes and showed the method outperformed the Cox regression. However, that method is
only for gene selections and can not be directly used for
identifying pathways without additional criteria. Group
LASSO (L1) related penalized methods have been extensively studied recently in logistic regression [18], multiple kernel learning [19], and microarray analysis [20]
with binary phenotypes. The methods are designed for
selecting groups of variables and identifying important
covariate groups (pathways). However, LASSO is biased.
L p (p ≤ 1) (with one specific implementation entitled
adaptive LASSO [1,21]) is asymptotic unbiased and has
oracle properties. Therefore, it is reasonable to extend
the Lp to group Lp for pathway identifications. In this
paper, we therefore extend Lp to group Lp penalty and
develop a novel iterative gradient based algorithm for
GAUCS maximization (IGGAUCS), which can effectively integrate genomic data and biological pathway
information and identify disease associated pathways
with right censored survival data. In Section 2, we formulate the GAUCS maximization and group Lp penalty
model and propose an efficient EM algorithm for survival prediction. Its performance is compared with its
group lasso penalized Cox regression (implemented by
ourselves). We also propose an integrated algorithm
with GAUCS for microarray data analysis. The proposed
approach is demonstrated with simulation and gene
expression examples in Section 3. Concluding remarks
are discussed in Section 4.
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Group Lp Penalized GAUCS Maximization

Consider we have a set of n independent observations
{t i ,  i , x i}in=1 , where δ i is the censoring indicator and
t i is the survival time (event time) if δ i = 1 or
censoring time if δ i = 0, and x i is the m-dimensional
input vector of the ith sample. We denote
N *i (t ) = 1(t i ≤ t) and the corresponding increment
dN *i (t ) = N *i (t ) − N *i (t −) . The time-dependent sensitivity and specificity are defined by sensitivity (c, t):
Pr( Mi > c | t i = t ) = Pr( Mi > c | dN *i (t ) = 1) and specificity (c, t): (Pr( Mi ≤ c | t i > t ) = Pr( Mi ≤ c | N *i (t ) = 0) .
Here sensitivity measures the expected fraction of
subjects with a marker greater than c among the subpopulation of individuals who die (cases) at time t,
while specificity measures the fraction of subjects
with a marker less than or equal to c among those
who survive (controls) beyond time t. With this definition, a subject can play the role of a control for an
early time, t <t i , but then play the role of case when
t = t i . Then, ROC curves are defined as ROC t (q) =
TP t {[FP t ] -1 (q)} for q  [0, 1], and the area under the
1
ROC curve for time t is AUC ( t ) = ∫ ROC t (q)dq ,
0

where TPt and FP t are the true and false positive rate
at time t respectively, and [FPt]-1(q) = infc{c : FPt(c) ≤ q}.
ROC methods can be used to characterize the ability of a
marker to distinguish cases at time t from controls at time
t. However, in many applications there is no prior time t
identified and thus a global accuracy summary is defined
by averaging over t:
GAUCS = 2 ∫ AUC(t )g(t )S(t )dt
= Pr( M j > Mk | t j < t k ),

(1)

which indicates the probability that the subject who
died (cases) at the early time has a larger value of the
marker, where S(t) and g(t) are the survival and corresponding density functions, respectively.
Assuming there are r clusters in the input covariates,
our primary aim is to identify a small number of clusters associated with survival time ti. Mathematically, for
each input xi  Rm, we are given a decomposition of Rm
as a product of r clusters:
 m =  m1 ×  ×  m r , so that each data point x i can
be decomposed into r cluster components, i.e. x i =
(x i1 ,...,x ir ), where each x il is in general a vector. We
define M(x) = wT x to be the risk score function, where
w = (w 1, w 2 ,  , w r ) T ∈  m1 +,,+ m r is the vector of
coefficients that has the same cluster decomposition as
xi. We denote Mi = M(xi) for simplicity. Our goal is to
encourage the sparsity of vector w at the level of clusters; in particular, we want most of its multivariate components wl to be zero. The natural way to achieve this is
to explore the combination of Lp (0 ≤ p ≤ 1) norm and
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L 2 norm. Since w is defined by clusters, we define a
weighted group Lp norm

Ep =

1
N

r

Lp =

∑d |w | ,
p

l

l

1
=
N

l =1

where within every group, an L 2 norm is used
(| w l |= (w lT w l )1/2 ) and dl can be set to be 1 if all clusters are equally important. Note that group Lp = L2 if
r = 1 and dl = 1, and group Lp = Lp when r = m and dl
= 1. We can define the optimization problem
max GAUCS = max Pr( M j > Mk | t j < t k )
Lp <  ,

s.t.

(2)

where Mj = wT xj . The ideal situation is that M(xj) >
M(xk ) or wT (xj - xk) > 0, ∀ couple (xj, xk) with corresponding times tj <tk (or j <k) and δj = 1.
Pr(Mj >Mk|tj <tk) can be estimated as
GAUCS = Pr( M j > Mk|t j < t k )
j<k
∑
∑ n 1 M j > Mk
 j =1 k = 2
=
,
j<k
1
∑
∑n
 j =1 k = 2

(3)

where 1 a>b = 1 if a >b, and 0 otherwise. Obviously,
GAUCS is a measure to rank the patients’ survival time.
The perfect GAUCS = 1 indicates that the order of all
patients’ survival time are predicted correctly and
GAUCS = 0.5 indicates for a completely random choice.
One way to approximate step function 1 M j > M k is
1
to use a sigmoid function  ( z) =
− z and let
N = ∑ j<k

1+ e

∑ k =2 1 , then
 =1
n

j

GAUCS =

j<k
 (w T ( x j − x k ))
∑
∑n
k
2
=
 j =1
N

(4)

.

Equation (4) is nonconvex function and can only be
solved with the conjugate gradient method to find a
local minimum. Based on the property that the arithmetic average is greater than the geometric average, we
have
j<k
T
∑
∑n  (w ( x j − x k ))
 j =1 k = 2
N

≥

1
N

T

( x j − x k )).

j< k k =2
 j =1

We can, therefore, maximize the following log likelihood lower bound of equation (4).

∑ ∑ log  (w

T

(x j − x k )) − λL p

j< k k =2
 j =1
n

∑ ∑ log  (w

(5)

r

T

(x j − x k )) − λ

j< k k =2

∑d | w | ,
p

l

l

l =1

 j =1

where l is a penalized parameter controlling model
complexity. Equation (5) is the maximum a posterior
(MAP) estimator of w with Laplace prior provided we
treat the sigmoid function as the pair-wise probability,
i.e. Pr(Mj > Mk) = s(wT (xj - xk)). When p = 1, Ep is a
convex function. A global optimal solution is
guaranteed.
The IGGAUCS Algorithm

In order to find the w that maximizes E p, we need to
find the first order derivative. Since group Lp with p ≤ 1
is not differentiable at |wl| = 0, differentiable approximations of group L p is required. We propose a local
quadratic approximation for group |wl|p based on convex duality and local variational methods [23,24]. Fan
and Li [25] proposed a similar approximation for single
variable. The adaptive LASSO approach proposed by
Zou and Li [21] is a LASSO (linear bound) approximation for Lp penalty. The drawback with that approach is
that LASSO itself is not differentiable at |wl| = 0. Since
|wl|p is concave when p < 1, we can have
f (w l ) = | w l |p = min{ l |w l |2 − g( l )}
l

g( l ) = min{ l |  l |2 − f ( l )},

(6)

| l |

where the function g(.) is the dual function of f(.) in
variational analysis. Geometrically, g(hl) represents the
amounts of vertical shift applied to hl|wl|2 to obtain a
quadratic upper bound with precision parameter hl, that
touches f(w l ). Taking the first order derivative for
 l l2 − f ( l ) , the minimum occurs at a solution of stationary equation when θl ≠ 0,
2 l |  l | − f ′( l ) = 0 ⇒  l =

f ′( l )
,
2| l|

and f ′(θl) = p|θl |p-1. Substituting into f(wl), we have
the variational bound:

n

∏ ∏  (w

n

|w l|p ≤

f ′( l )
( | w l|2 − | l|2 ) + f ( l )
2 l

1
= {p | l |p −2 | w l|2 +(2 − p) |  l |p} ,
2

(7)

Liu et al. Algorithms for Molecular Biology 2010, 5:30
http://www.almob.org/content/5/1/30

Page 4 of 13

where θl denote variational parameters. With the local
quadratic bound, we have the following smooth lower
bound.
1
Ep =
N

≥

1
N

n

∑ ∑ log  (w

(x j − x k )) − 

j< k k =2
 j =1

∑d |w |

p

l

l

l =1

n

∑ ∑ log  (w

T

(x j − x k ))

(8)

j< k k =2
 j =1
r

−

r

T

∑ 2l {p |  |
d

l

p −2

| w l |2 +(2 − p) |  l |p}

l =1

= E(w ,  ).

In equation (8), the lower bound E(w, θ) is differentiable w.r.t both w and θ. We therefore propose a EM
algorithm to maximize E(w, θ) w.r.t w while keeping θ
fixed and maximize E(w, θ) w.r.t the variational parameter θ to tighten the variational bound while keeping
w fixed. Convergence to the local optimum is guaranteed. Since maximization w.r.t the variational parameters
0 = (|θ1|,|θ2|,..., |θr|), with w being fixed, can be solved
with the stationary equation

∂E( w , )
∂| l |

= 0 we have θl =

wl, for l = 1, 2,..., r.
Given r candidate pathways potentially associated with
the survival time, ml survival associated genes with the
expression of xl on each pathway l (l = 1, 2,..., r), and
letting w = (w 1 , w 2 ,..., w r ) T be a vector of the corresponding coefficients and g(w) = ∂ w E(w , ) , we have
∂w
the following iterative gradient algorithm for E(w, θ)
maximization:
The IGGAUCS Algorithm

Given p, l, and  = 10-6, initializing w 1 = (w 11 , w 12 ,  , w 1r ) T
randomly with nonzero w 1l , l = 1,  , r , and set θ1 = w1.
Update w with θ fixed:
wt+1 = wt + atdt, where t: the number of iterations
and at: the step size, dt is updated with the conjugate gradient method:
dt = g(wt) + utdt and u t =

[ g( w t ) − g( w t −1)]T g( w t )
g( w t −1) T g( w t −1)

.

Update θ with w fixed:
θt+1 = wt+1
Stop when |w t+1 - w t | <  or maximal number of
iterations exceeded.

Choice of Parameters

There are two parameters p and l in this method,
which can be determined through 10-fold cross validation. One efficient way is to set p = 0.1, 0.2,..., and 1
respectively, and search for an optimal l for each p
using cross validation. The best (p, l) pair will be found
with the maximal test GAUCS value. Theoretically when
p = 1, E(w, θ) is convex and we can find the global maximum easily, but the solution is biased and small values
of p would lead to better asymptotic unbiased solutions.
Our results with limited experiments show that optimal
p usually happens at a small p such as p = 0.1. For comparison purposes, we implement the popular Cox
regression with group LASSO (GL1Cox), since there is
no software available in the literature. Our implementation is based on group LASSO penalized partial log-likelihood maximization. The best l is searched from l 
[0.1, 25] for IGGAUCS and from l  [0.1, 40] for
GL1Cox method with the step size of 0.1, as the Lp penalty goes to zero much quicker than L1. We suggest that
the larger step size such as 0.5 can be used for most
applications, since the test GAUCS does not change dramatically with a small change of l.

Computational Results
Simulation Data

We first perform simulation studies to evaluate how
well the IGGAUCS procedure performs when input data
has a block structure. We focus on whether the important variable groups that are associated with survival
outcomes can be selected using the IGGAUCS procedure and how well the model can be used for predicting
the survival time for future patients. In our simulation
studies, we simulate a data set with a sample size of 100
and 300 input variables with 100 groups (clusters). The
triple variables x 1 - x 3 , x 4 - x 6 , x 7 - x 9 ,..., x 298 - x 300
within each group are highly correlated with a common
correlation g and there are no correlations between
groups. We set g = 0.1 for weak correlation, g = 0.5 for
moderate, and g = 0.9 for strong correlation in each triple group and generate training and test data sets of
sample size 100 with each g respectively from a normal
distribution with the band correlation structure. We
assume that the first three groups(9 covariates) (x1 - x3,
x4 - x6, x7 - x9) are associated with survival and the 9
covariates are set to be w = [-2.9 2.1 2.4 1.6 -1.8 1.4 0.4
0.8 -0.5] t . With this setting, 3 covariates in the first
group have the strongest association (largest covariate
values) with survival time and 3 covariates in group 3
have less association with survival time. The survival
time is generated with H = 100 exp(-wT x + ε) and the
Weibull distribution, and the census time is generated
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from 0.8*median(time) plus a random noise. Based on
this setting, we would expect about 25% - 35% censoring. To compare the performance of IGGAUCS and
GL1Cox, we build the model based on training data set
and evaluate the model with the test data set. We repeat
this procedure 100 times and use the time-independent
GAUCS to assess the predictive performance.
We first compare the performance of IGGAUCS and
GL 1 Cox methods with the frequency of each of these
three groups being selected under two different correlation structures based on 100 replications. The results
are in Table 1. Table 1 shows that IGGAUCS with p =
0.1 outperforms the GL 1 Cox in that IGGAUCS can
identify the true group structures more frequently under
different inner group correlation structures. Its performance is much better than GL 1 Cox regression, when
the inner correlation in a group is high (g = 0.9) and the
variables within a group have weak association with survival time.
To compare more about the performance of
IGGAUCS and GL 1 Cox in parameter estimation, we
show the results for each parameter with different inner
correlation structures (0.1, 0.5, 0.9) in Figure 1. For each
parameter in Figure 1, the left bar represents the parameter estimated from GL 1 Cox, the middle bar is the
true value of the parameter, and the right bar indicates
parameter estimated from IGGAUCS. We observe that
both the GL1Cox and IGGAUCS methods estimated the
sign of the parameters correctly for the first two groups.
However both methods can only estimate the sign of w8
correctly in group 3 with smaller coefficients. Moreover,
ŵ estimated from IGGAUCS is much closer to the true
w than that from GL1Cox, especially when the covariates are larger. This indicates that the Lp (p = 0.1) penalty is less biased than the L1 penalty. The estimators of
IGGAUCS are larger than that of GL1 Cox with weak,
moderate, and strong correlations. Finally, the test global AUC summaries (GAUCSs) of IGGAUCS and
GL1Cox with 100 replications are shown in Table 2.
Table 1 Frequency of Three Survival Associated Groups
Selected in 100 Replications
IGGAUCS/GL1Cox
Parameters

g = 0.1

g = 0.5

g = 0.9

100/100

100/100

100/100

100/78

100/84

100/96

47/2

53/4

94/24

w1 = -2.9
w2 = 2.1
w3 = 2.4
w4 = 1.6
w5 = -1.8
w6 = 1.4
w7 = 0.4
w8 = 0.8
w9 = -0.5

Table 2 shows that IGGAUCS performs better than
GL 1 Cox regression. This is reasonable, since our
method, unlike Cox regression which maximizes a partial log likelihood, directly maximizes the penalized
GAUCS. One interesting result is that the test GAUCSs
become smaller as the inner group correlation coefficient g increases from 0.1 to 0.9. We also apply the gene
harvesting method proposed by Hastie et al. (2001) and
discussed by Segal (2006) [7,26] to the simulation data,
but don’t show the results in Table 2. The gene harvest
method uses the average gene expression in each group
(cluster) and ignore the variance among genes within
the group. The prediction performances are poor with
test GAUCS of 0.57 ± 0.02 and 0.65 ± 0.016 respectively, when the correlations among genes are weak (g =
0.1) and moderate (g = 0.5). Its performance is slightly
better with the test GAUCS of 0.75 ± 0.024, when g =
0.9, but this4 performance is still not as good as either
IGGAUCS or GL 1 Cox. One explantation is that the
group is more heterogeneous with weaker correlations
among variables, and the average does not provide a
meaningful summary. Moreover, we cannot identify the
survival association of individual variables using gene
harvesting.
Follicular Lymphoma (FL) Data

Follicular lymphoma is a common type of Non-Hodgkin
Lymphoma (NHL). It is a slow growing lymphoma that
arises from B-cells, a type of white blood cell. It is also
called an “indolent” or “low-grad” lymphoma for its
slow nature, both in terms of its behavior and how it
looks under the microscope. A study was conducted to
predict the survival probability of patients with gene
expression profiles of tumors at diagnosis [27].
Fresh-frozen tumor biopsy specimens and clinical data
were obtained from 191 untreated patients who had
received a diagnosis of follicular lymphoma between
1974 and 2001. The median age of patients at diagnosis
was 51 years (range 23 - 81) and the median follow up
time was 6.6 years (range less than 1.0 - 28.2). The median follow up time among patients alive was 8.1 years.
Four records with missing survival information were
excluded from the analysis. Affymetrix U133A and
U133B microarray gene chips were used to measure
gene expression levels from RNA samples. A log 2
transformation was applied to the Affymetrix measurement. Detailed experimental protocol can be found in
Dave et al. 2004. The data set was normalized for each
gene to have mean 0 and variance 1. Because the data is
very large and there are many genes with their expressions that either do not change cross samples or change
randomly, we filter out the genes by defining a correlation measure with GAUCS for each gene xi R(t, x i ) =
|2GAUCS(t, xi) - 1|, where R = 1 when GAUCS = 0, or
1 and R = 0 when GAUCS = 0.5 (gene x i is not
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Figure 1 True and Estimated Parameters. The true and estimated parameters with the simulation data are shown in Figure 2. The left bars
represent each parameter estimated from GL1Cox, the middle bars are the true value of the parameter, and the right bars indicate parameters
estimated form IGGAUCS.

associated with the survival time). We perform the permutation test 1000 times for R to identify 2150 probes
associated with survival time. We then identify 49 candidate pathways with 5 and more genes using DAVID.
There are total 523 genes on the candidate pathways.
Since a gene can be involved in more than one pathway,
the number of distinguished genes should be a little less
than 500. The 49 biological pathways are given in Table
3. We finally apply IGGAUCS to identify the small
number of biological pathways associated with survival
Table 2 Test GAUCS of Simulated Data with Different
Correlation Structures
Correlation

IGGAUCS

GL1Cox

g = 0.1

0.921(±0.023)

0.897(±0.031)

g = 0.5

0.889(±0.021)

0.871(±0.024)

g = 0.9

0.866(±0.017)

0.828(±0.025)

phenotypes. We first randomly divide the data into two
subsets, one for training with 137 samples, and the
other for testing with 50 samples. To avoid overfitting
and bias from a particular partition, we randomly partition the data 50 times to estimate the performance of
the model with the average of the test GAUCS. The regularization parameter l is tuned using 10-fold crossvalidation with training data only.
Since it is possible different pathways may be selected
in the cross validation procedure, the relevance count
concept [28] was utilized to count how many times a
pathway is selected in the cross validation. Clearly, the
maximum relevance count for a pathway is 200 with the
10-fold cross validation and 20 repeating. We have
selected 8 survival associated pathways with IGGAUCS.
The average test GAUCS is 0.892 ± 0.013. Moreover,
the parameters (weights) wi and corresponding genes on
each pathway indicate the association strength and
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Table 3 Candidate Survival Associated Pathways
Pathways

# of Genes

Pathways

# of Genes

Propanoate metabolism

5

Melanoma

10

Type II diabetes mellitus

6

Thyroid cancer

5

Adipocytokine signaling pathway

10

Prostate cancer

13

Melanogenesis

13

Glycolysis/Gluconeogenesis

8

GnRH signaling pathway

11

Butanoate metabolism

6

Insulin signaling pathway

15

Endometrial cancer

11

Sphingolipid metabolism

5

Pancreatic cancer

10

Glycerophospholipid metabolism
T cell receptor signaling pathway

9
11

Colorectal cancer
RNA polymerase

12
6

Hematopoietic cell lineage

10

Huntington’s disease

5

Glycerolipid metabolism

6

Focal adhesion

20

Toll-like receptor signaling pathway

13

Apoptosis

12

Antigen processing and presentation

9

Adherens junction

10

Complement and coagulation cascades

8

Tryptophan metabolism

7

ECM-receptor interaction

14

Histidine metabolism

6

Wnt signaling pathway
Ubiquitin mediated proteolysis

20
15

Fatty acid metabolism
Acute myeloid leukemia

10
9

Neuroactive ligand-receptor interaction

28

Bladder cancer

6

gamma-Hexachlorocyclohexane degradation

5

Focal adhesion

20

Calcium signaling pathway

21

ErbB signaling pathway

11

MAPK signaling pathway

31

PPAR signaling pathway

16

Valine, leucine and isoleucine degradation

6

Glioma

7

Pyrimidine metabolism

12

Chronic myeloid leukemia

10

Glycan structures - degradation
Porphyrin and chlorophyll metabolism

5
7

Non-small cell lung cancer

11

direction between genes and the survival time. Positive
wis indicate that patients with high expression level die
earlier and negative w i s represent that patients live
longer with relatively high expression levels. The absolute values of |wi| indicate the strength of association
between survival time and the specific gene. Genes on
the pathway, estimated parameters, and relevance
accounts are given in Table 4.
The eight KEGG pathways identified play an important role in patient survivals and they can be ranked
with the average |wj |:∑j |wj |/L, where L is the number
of genes on a pathway as shown in Table 5. The identified 8 KEGG pathways fall into three categories (i) signaling molecules and interaction including the MAPK
signaling pathway, the Calcium signaling pathway, Focal
adhesion, ECM-receptor interactions and neuroactive
ligand-receptor interactions, (ii) metabolic pathways
including Fatty acid metabolism and Porphyrin and
chlorophyll metabolism, and (iii) nitric oxide and cell
stress including Ubiquitin mediated proteolysis. These
pathways are involved in different aspects of genetic
functions and are vital for cancer patient survivals. We
only discuss the MAPK signaling pathway but others
can be analyzed in a similar fashion. The top-rank
MAPK signaling pathway transduces a large variety of

external signals, leading to a wide range of cellular
responses, including growth, differentiation, inflammation, and apoptosis invasiveness and ability to induce
neovascularization. MAPK signaling pathway has been
linked to different cancers including follicular lymphoma
[29]. The pathway and genes on pathways are given in
Figure 2.
Genes in red color are highly expressed in patients
with aggressive FL and genes in yellow are highly
expressed in the earlier stage of FL cancers. Many
important cancer related genes are identified with our
methods. For example, SOS1, one of the RAS genes (e.
g., MIM 190020), encodes membrane-bound guanine
nucleotide-binding proteins that function in the transduction of signals that control cell growth and differentiation. Binding of GTP activates RAS proteins, and
subsequent hydrolysis of the bound GTP to GDP and
phosphate inactivates signaling by these proteins. GTP
binding can be catalyzed by guanine nucleotide
exchange factors for RAS, and GTP hydrolysis can be
accelerated by GTPase-activating proteins (GAPs). SOS1
plays a crucial role in the coupling of RTKs and also
intracellular tyrosine kinases to RAS activation. The
deregulation of receptor tyrosine kinases (RTKs) or
intracellular tyrosine kinases coupled to RAS activation
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Table 4 Genes on pathway, relevance accounts, and estimated parameters
wi

GeneID

Gene Name

ECM-receptor interaction (relevance counts: 200)
0.2239

CD36

cd36 antigen (collagen type i receptor, thrombospondin receptor)

0.0409

FNDC1

fibronectin type iii domain containing 1

0.0746

SV2C

synaptic vesicle glycoprotein 2c

0.0804

SDC1

syndecan 1

-0.1255

FN1

fibronectin 1

0.0211

LAMC1

laminin, gamma 1 (formerly lamb2)

-0.0854
-0.1130

GP5
CD47

glycoprotein v (platelet)
cd47 antigen (rh-related antigen, integrin-associated signal transducer)

-0.1296

THBS2

thrombospondin 2

-0.0547

COL1A2

collagen, type i, alpha 2

-0.1024

COL5A2

collagen, type v, alpha 2

0.0861

LAMB4

laminin, beta 4

-0.0315

COL1A1

collagen, type i, alpha 1

0.0395

AGRN

agrin RG

Focal adhesion (relevance counts 145)
0.0054

PAK3

p21 (cdkn1a)-activated kinase 3

0.0446

PIK3R3

phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma)

0.0044

PDPK1

3-phosphoinositide dependent protein kinase-1

-0.0045

BAD

bcl2-antagonist of cell death

0.0087

PARVA

parvin, alpha

-0.0144

FN1

fibronectin 1

0.0041

LAMC1

laminin, gamma 1 (formerly lamb2)

-0.0202
-0.0158

PARVG
THBS2

parvin, gamma
thrombospondin 2

0.0134

PPP1R12A

protein phosphatase 1, regulatory (inhibitor) subunit 12a

-0.0044

SOS1

son of sevenless homolog 1 (drosophila)

-0.0084

COL1A2

collagen, type i, alpha 2

-0.0122

COL5A2

collagen, type v, alpha 2

0.0091

LAMB4

laminin, beta 4 RG Homo sapiens

-0.0068

RAF1

v-raf-1 murine leukemia viral oncogene homolog 1

-0.0038
-0.0034

ACTN1
COL1A1

actinin, alpha 1
collagen, type i, alpha 1

-0.0067

GSK3B

glycogen synthase kinase 3 beta

-0.0065

MAPK8

mitogen-activated protein kinase 8

-0.0030

MYL7

myosin, light polypeptide 7, regulatory

Neuroactive ligand-receptor interaction (relevance counts: 200)
0.0894

P2RY6

pyrimidinergic receptor p2y, g-protein coupled, 6

-0.2753
0.1648

PTAFR
GLRA3

platelet-activating factor receptor
glycine receptor, alpha 3

0.0857

FPRL1

formyl peptide receptor-like 1

-0.1783

EDNRA

endothelin receptor type a

0.3233

HRH4

histamine receptor h4

0.2106

GRM2

glutamate receptor, metabotropic 2

-0.1112

GRIN1

glutamate receptor, ionotropic, n-methyl d-aspartate 1

-0.0220

PTHR1

parathyroid hormone receptor 1

0.0971
-0.4303

OPRM1
CTSG

opioid receptor, mu 1
cathepsin g

-0.0404

P2RY8

purinergic receptor p2y, g-protein coupled, 8

-0.0783

BDKRB1

bradykinin receptor b1

0.3247

FSHR

follicle stimulating hormone receptor
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Table 4 Genes on pathway, relevance accounts, and estimated parameters (Continued)
-0.1430

ADRA1B

adrenergic, alpha-1b-, receptor

0.1464

C3AR1

complement component 3a receptor 1

0.1120

P2RX2

purinergic receptor p2x, ligand-gated ion channel, 2

0.0311
0.2646

AVPR1B
FPR1

arginine vasopressin receptor 1b
formyl peptide receptor 1

0.2003

GABRA5

gamma-aminobutyric acid (gaba) a receptor, alpha 5

-0.0278

PRLR

prolactin receptor

-0.1070

ADORA1

adenosine a1 receptor

0.2652

HTR7

5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled)

-0.0194

GABRA4

gamma-aminobutyric acid (gaba) a receptor, alpha 4

0.0145

GHRHR

growth hormone releasing hormone receptor

-0.3163
-0.0760

MAS1
PTGER3

mas1 oncogene
prostaglandin e receptor 3 (subtype ep3)

0.2196

PARD3

par-3 partitioning defective 3 homolog (c. elegans)

Ubiquitin mediated proteolysis (relevance counts: 200)
0.0186

UBE2B

ubiquitin-conjugating enzyme e2b (rad6 homolog)

-0.0677

CUL4A

cullin 4a

0.0051

PML

promyelocytic leukemia

-0.1023

UBE3B

ubiquitin protein ligase e3b

-0.1581
0.1390

UBE3C
BTRC

ubiquitin protein ligase e3c
beta-transducin repeat containing

-0.0669

HERC3

hect domain and rld 3

0.00009

RBX1

ring-box 1

0.0011

CUL5

cullin 5

0.0267

ANAPC4

anaphase promoting complex subunit 4

-0.0253

UBE2L3

ubiquitin-conjugating enzyme e2l 3

0.0096

KEAP1

kelch-like ech-associated protein 1

-0.0267
0.0116

UBE2E1
CBL

ubiquitin-conjugating enzyme e2e 1 (ubc4/5 homolog, yeast)
cas-br-m (murine) ecotropic retroviral transforming sequence

0.0328

BIRC6

baculoviral iap repeat-containing 6 (apollon)

Porphyrin and chlorophyll metabolism (relevance counts: 185)
0.0330

BLVRA

biliverdin reductase a

-0.0103

FTH1

ferritin, heavy polypeptide 1

0.0227

ALAD

aminolevulinate, delta-, dehydratase

0.1983
0.0070

HMOX1
UROS

heme oxygenase (decycling) 1
uroporphyrinogen iii synthase (congenital erythropoietic porphyria)

-0.1596

GUSB

glucuronidase, beta

0.0077

UGT2B15

udp glucuronosyltransferase 2 family, polypeptide b15

Calcium signaling pathway (relevance counts: 200)
-0.0025

BST1

0.0003

BDKRB1

bone marrow stromal cell antigen 1
bradykinin receptor b1

-0.0016

PTAFR

platelet-activating factor receptor

-0.0002
-0.0007

ADRA1B
PPP3CC

adrenergic, alpha-1b-, receptor
protein phosphatase 3 (formerly 2b), catalytic subunit, gamma isoform

-0.0001

ADCY7

adenylate cyclase 7

0.0008

GNA11

guanine nucleotide binding protein (g protein), alpha 11 (gq class)

-0.0013

AVPR1B

arginine vasopressin receptor 1b

0.0014

P2RX2

purinergic receptor p2x, ligand-gated ion channel, 2

-0.0013

CACNA1E

calcium channel, voltage-dependent, alpha 1e subunit

0.0004

EDNRA

endothelin receptor type a

0.00009
0.0006

SLC8A1
CACNA1B

solute carrier family 8 (sodium/calcium exchanger), member 1
calcium channel, voltage-dependent, l type, alpha 1b subunit
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Table 4 Genes on pathway, relevance accounts, and estimated parameters (Continued)
-0.0013

PLCD1

phospholipase c, delta 1

-0.0029

HTR7

5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled)

0.0014

GRIN1

glutamate receptor, ionotropic, n-methyl d-aspartate 1

0.0028
-0.0024

CAMK2A
CACNA1I

calcium/calmodulin-dependent protein kinase (cam kinase) ii alpha
calcium channel, voltage-dependent, alpha 1i subunit

-0.0002

TNNC1

troponin c type 1 (slow)

0.0009

PTGER3

prostaglandin e receptor 3 (subtype ep3)

0.0012

CACNA1F

calcium channel, voltage-dependent, alpha 1f subunit

Fatty acid metabolism (relevance counts: 192)
0.0043

ACSL3

acyl-coa synthetase long-chain family member 3

0.0675

ALDH2

aldehyde dehydrogenase 2 family (mitochondrial)

-0.0491
0.0120

ACAT2
ALDH1B1

acetyl-coenzyme a acetyltransferase 2 (acetoacetyl coenzyme a thiolase)
aldehyde dehydrogenase 1 family, member b1

0.0597

CYP4A11

cytochrome p450, family 4, subfamily a, polypeptide 11

-0.1447

ACADSB

acyl-coenzyme a dehydrogenase, short/branched chain

0.0736

CPT1A

carnitine palmitoyltransferase 1a (liver)

0.1075

CPT1B

carnitine palmitoyltransferase 1b (muscle)

-0.0366

ACADVL

acyl-coenzyme a dehydrogenase, very long chain

0.2168

ADH4

alcohol dehydrogenase 4 (class ii), pi polypeptide

MAPK signaling pathway (relevance counts: 200)
-0.1570

PLA2G10

phospholipase a2, group x

-0.2415

MAPKAPK5

mitogen-activated protein kinase-activated protein kinase 5

-0.1636

IL1B

interleukin 1, beta

-0.0651

ZAK

sterile alpha motif and leucine zipper containing kinase azk

0.0572

PPP3CC

protein phosphatase 3 (formerly 2b), catalytic subunit, gamma isoform

-0.0674

MAP3K2

mitogen-activated protein kinase kinase kinase 2

-0.1729
-0.1718

JUND
SOS1

jun d proto-oncogene
son of sevenless homolog 1 (drosophila)

0.1082

FGF14

fibroblast growth factor 14

0.3102

PTPN5

protein tyrosine phosphatase, non-receptor type 5

-0.3903

CACNB1

calcium channel, voltage-dependent, beta 1 subunit

0.2678

MAP3K7

mitogen-activated protein kinase kinase kinase 7

0.3176

CACNG8

calcium channel, voltage-dependent, gamma subunit 8

0.0893

FGF19

fibroblast growth factor 19

-0.0853
0.0215

RRAS2
NLK

related ras viral (r-ras) oncogene homolog 2
nemo-like kinase

0.0452

MAP4K4

mitogen-activated protein kinase kinase kinase kinase 4

0.1639

CACNA1E

calcium channel, voltage-dependent, alpha 1e subunit

-0.0290

ARRB1

arrestin, beta 1

-0.1169

STK4

serine/threonine kinase 4

0.1008

CACNA1B

calcium channel, voltage-dependent, l type, alpha 1b subunit

0.0839

MOS

v-mos moloney murine sarcoma viral oncogene homolog

-0.1244
0.1572

MEF2C
RAF1

mads box transcription enhancer factor 2, polypeptide c
v-raf-1 murine leukemia viral oncogene homolog 1

0.1757

MAPK8IP1

mitogen-activated protein kinase 8 interacting protein 1

0.2908

IKBKB

inhibitor of kappa light polypeptide gene enhancer in b-cells, kinase beta

-0.3452

CACNA1I

calcium channel, voltage-dependent, alpha 1i subunit

-0.2473

MAPK8

mitogen-activated protein kinase 8

-0.2339

CACNA1F

calcium channel, voltage-dependent, alpha 1f subunit

0.0979

CD14

cd14 antigen

-0.1047

MRAS

muscle ras oncogene homolog
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Table 5 Pathway Ranks
Pathway

∑j |wj|/L

Rank

MAPK signaling pathway

0.1614

1

Neuroactive ligand-receptor interaction

0.1562

2

ECM-receptor interaction

0.0863

3

Fatty acid metabolism

0.0772

4

Porphyrin and chlorophyll metabolism

0.0627

5

Ubiquitin mediated proteolysis

0.0494

6

Focal adhesion

0.0100

7

Calcium signaling pathway

0.0012

8

has been involved in the development of a number of
tumors, such as those in breast cancer, ovarian cancer
and leukemia. Another gene, IL1B, is one of a group of
related proteins made by leukocytes (white blood cells)
and other cells in the body. IL1B, one form of IL1, is
made mainly by one type of white blood cell, the macrophage, and helps another type of white blood cell, the

lymphocyte, fight infections. It also helps leukocytes
pass through blood vessel walls to sites of infection and
causes fever by affecting areas of the brain that control
body temperature. IL1B made in the laboratory is used
as a biological response modifier to boost the immune
system in cancer therapy.
As shown in Figure 2, the genes SOS1, IL1B, RAS,
CACNB1, MEF2C, JUND, and MAPKAPK5 are highly
expressed in patients who were diagnosed earlier and
lived longer and the genes FGF14, PTPN5, MOS,
RAF1, CD14 are highly expressed in patients who were
diagnosed at more aggressive stages and died earlier,
which may indicate that oncogenes such such SOS1,
JUND, and RAS may initialize FL cancer and genes
such as MOS, IKK, and CD14 may cause FL cancer to
be more aggressive. There are several causal relations
among the identified genes on MAPK. For instance,
the down-expressed SOS and RAS cause the upexpressed RAF1 and MOS and the up-stream gene IL1

Figure 2 MAPK Signaling Pathway. MAPK signaling pathway and the associated genes. Genes in red are highly expressed in patients who
died earlier and genes in yellow are highly expressed in patients who lived longer.
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is coordinately expressed with CASP and the gene
MST1/2.

Conclusions
Since a large amount of biological information on various aspects of systems and pathways is available in public databases, we are able to utilize this information in
modeling genomic data and identifying pathways and
genes and their interactions that might be related to
patient survival. In this study, we have developed a
novel iterative gradient algorithm for group Lp penalized
global AUC summary (IGGAUCS) maximization methods for gene and pathway identification, and for survival
prediction with right censored survival data and high
dimensional gene expression profile. We have demonstrated the applications of the proposed method with
both simulation and the FL cancer data set. Empirical
studies have shown the proposed approach is able to
identify a small number of pathways with nice prediction performance. Unlike traditional statistical models,
the proposed method naturally incorporates biological
pathways information and it is also different from the
commonly used Gene Set Enrichment Analysis (GSEA)
in that it simultaneously considers multiple pathways
associated with survival phenotypes.
With comprehensive knowledge of pathways and
mammalian biology, we can greatly reduce the hypothesis space. By knowing the pathway and the genes that
belong to particular pathways, we can limit the number
of genes and gene-gene interactions that need to be
considered in modeling high dimensional microarray
data. The proposed method can efficiently handle thousands of genes and hundreds of pathways as shown in
our analysis of the FL cancer data set.
There are several directions for our future investigations. For instance, we may want to further investigate
the sensitivity of the proposed methods to the misspecification of the pathway information and misspecification
of the model. We may also extend our method to incorporate gene-gene interactions and gene (pathway)environmental interactions.
Even though we have only applied our methods to
gene expression data, it is straightforward to extend our
methods to SNP, miRNA CGH, and other genomic data
without much modification.
Acknowledgements
We thank the Associate Editor and the two anonymous referees for their
constructive comments which helped improve the manuscript. ZL was
partially supported by grant 1R03CA133899-01A210 from the National
Cancer Institute.
Author details
1
Greenebaum Cancer Center, University of Maryland, 22 South Greene Street,
Baltimore, MD 21201, USA. 2Department of Epidemiology and Preventive

Page 12 of 13

Medicine, The University of Maryland, Baltimore, MD 21201, USA. 3Division of
Biostatistics, Department of Pharmacology and Experimental Therapeutics,
Thomas Jefferson University, Philadelphia, PA 19107, USA. 4Department of
Oncology and Diagnosis Sciences, The University of Maryland Dental School,
Baltimore, MD 21201, USA.
Authors’ contributions
ZL designed the method and drafted the manuscript. Both LSM and TH
participated manuscript preparation and revised the manuscript critically. LM
provided important help in its biological contents. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 January 2010 Accepted: 16 August 2010
Published: 16 August 2010
References
1. Zou H: The Adaptive Lasso and its Oracle Properties. Journal of the
American Statistical Association 2006, 101(476):1418-1429.
2. Kanehisa L, Goto S: KEGG: Kyoto encyclopedia of genes and genomes.
Nucleic Acids Research 2002, 28:27-30.
3. Tibshirani R: Regression shrinkage and selection via the lasso. J Royal
Statist Soc B 1996, 58(1):267-288.
4. Tibshirani R: The lasso method for variable selection in the Cox model.
Statistics in Medicine 1997, 16(4):385-95.
5. Gui J, Li H: Variable Selection via Non-concave Penalized Likelihood and
its Oracle Properties. Journal of the American Statistical Association, Theory
and Methods 2001, 96:456.
6. Van Houwelingen H, Bruinsma T, Hart A, Van’t Veer L, Wessels L: Crossvalidated Cox regression on microarray gene expression data. Stat Med
2006, 25:3201-3216.
7. Segal M: Microarray gene expression data with linked survival
phenotypes: diffuse large-B-cell lymphoma revisited. Biostatistics 2006,
7:268-285.
8. Ma S, Huang J: Additive risk survival model with microarray data. BMC
Bioinformatics 2007, 8:192.
9. Liu Z, Jiang F: Gene identification and survival prediction with Lp Cox
regression and novel similarity measure. Int J Data Min Bioinform 2009,
3(4):398-408.
10. Park M, Hastie T: L1 regularization path algorithm for generalized linear
models. J R Stat Soc B 2007, 69:659-677.
11. Sohn I, Kim J, Jung S, Park C: Gradient Lasso for Cox Proportional Hazards
Model. Bioinformatics 2009, 25(14):1775-1781.
12. Heagerty P, Zheng Y: Survival model predictive accuracy and ROC curves.
Biometrics 2005, 61(1):92-105.
13. Tian L, Greenberg S, Kong S, Altschuler J, Kohane I, Park P: Discovering
statistically significant pathways in expression profiling studies. PNAS
2005, 103:13544-13549.
14. Wei Z, Li H: Nonparametric pathways-based regression models for
analysis of genomic data. Biostatistics 2007, 8(2):265-284.
15. Pepe M: The Statistical Evaluation of Medical Tests for Classification and
Prediction Oxford: Oxford University Press 2003.
16. Pepe M: Evaluating technologies for classification and prediction in
medicine. Stat Med 2005, 24(24):3687-3696.
17. Liu Z, Gartenhaus R, Chen X, Howell C, Tan M: Survival Prediction and
Gene Identification with Penalized Global AUC Maximization, Journal of
Computational Biology. Journal of Computational Biology 2009,
16(12):1661-1670.
18. Meier L, van de Geer S, Buhlmann P: The group lasso for logistic
regression. Journal of the Royal Statistical Society: Series B (Statistical
Methodology) 2008, 70(1):53-71(19).
19. Bach F: Consistency of the Group Lasso and Multiple Kernel Learning.
The Journal of Machine Learning Research 2008, 9:1179-1225.
20. Ma S, Song X, Huang J: Supervised group Lasso with applications to
microarray data analysis. BMC Bioinformatics 2007, 8:60.
21. Zou H, Li R: One-step sparse estimates in non-concave penalized
likelihood models. The Annals of Statistics 2008, 36(4):1509-1533.

Liu et al. Algorithms for Molecular Biology 2010, 5:30
http://www.almob.org/content/5/1/30

Page 13 of 13

22. Liu Z, Tan M: ROC-Based Utility Function Maximization for Feature
Selection and Classification with Applications to High-Dimensional
Protease Data. Biometrics 2008, 64(4):1155-1161.
23. Jordan M, Ghahramani Z, Jaakkola T, Saul L: An Introduction to Variational
Methods for Graphical models. Learning in Graphical Models Cambridge:
The MIT PressJordan M 1998.
24. Kaban A, Durrant R: Learning with Lq < 1 vs L1-norm regularization with
exponentially many irrelevant features. Proc of the 19th European
Conference on Machine Learning (ECML08) 2008, 15-19.
25. Fan J, Li R: Penalized Cox Regression Analysis in the High-Dimensional
and Low-sample Size Settings, with Applications to Microarray Gene
Expression Data. Bioinformatics 2005, 21:3001-3008.
26. Hastie T, Tibashirani DR, Botstein , Brown P: Supervised harvesting of
expression trees. Genome Biology 2001, 2:3.1-3.12.
27. Dave S, Wright G, Tan B, Rosenwald A, Gascoyne R, Chan W, Fisher R,
Braziel R, Rimsza L, Grogan T, Miller T, LeBlanc M, Greiner T,
Weisenburger D, Lynch J, Vose J, Armitage J, Smeland E, Kvaloy S, Holte H,
Delabie J, Connors J, Lansdorp P, Ouyang Q, Lister T, Davies A, Norton A,
Muller-Hermelink H, Ott G, Campo E, Montserrat E, Wilson W, Jaffe E,
Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt L:
Prediction of survival in follicular lymphoma based on molecular
features of tumor-infiltrating immune cells. N Engl J Med 2004,
351(21):2159-2169.
28. Liu Z, Jiang F, Tian G, Wang S, Sato F, Meltzer S, Tan M: Sparse logistic
regression with Lp penalty for biomarker identification. Statistical
Applications in Genetics and Molecular Biology 2007, 6(1):Article 6.
29. Elenitoba-Johnson K, Jenson S, Abbott R, Palais R, Bohling S, Lin Z, Tripp S,
Shami P, Wang L, Coupland R, Buckstein R, Perez-Ordonez B, Perkins S,
Dube I, Lim M: Involvement of multiple signaling pathways in follicular
lymphoma transformation: p38-mitogen-activated protein kinase as a
target for therapy. Proc Natl Acad Sci USA 2003, 100(12):7259-64.
doi:10.1186/1748-7188-5-30
Cite this article as: Liu et al.: Survival associated pathway identification
with group Lp penalized global AUC maximization. Algorithms for
Molecular Biology 2010 5:30.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

